
YourChoice Therapeutics
YourChoice Therapeutics is a YC Winter 2019 (W19) company. Based in Berkeley, CA, USA. Team of 3.
About YourChoice Therapeutics
Summary
YourChoice Therapeutics develops non-hormonal contraceptives for both men and women. Its lead candidate, YCT-529, is an oral, once-daily pill for men that blocks RAR-alpha, a receptor required for sperm production, with reversible effect in preclinical studies. The company targets the gap left by 60-plus years of hormonal female contraception and a male market served only by condoms and vasectomy.
Go-to-market
YourChoice Therapeutics advances YCT-529 through clinical trials, currently in Phase 2, sponsoring and collaborating on studies that evaluate safety, tolerability, and pharmacokinetics before any commercial launch.
From the Y Combinator listing
YourChoice therapeutics is revolutionizing the contraceptive market…
YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.
Facts
- Healthcare / Healthcare -> Therapeutics
- Berkeley, CA, USA
- 3
- Active
- Early
Founders (2)
- Akash Bakshi
- Nadja Mannowetz
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works